These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23361368)

  • 1. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
    Kumar K; Wigfield S; Gee HE; Devlin CM; Singleton D; Li JL; Buffa F; Huffman M; Sinn AL; Silver J; Turley H; Leek R; Harris AL; Ivan M
    J Mol Med (Berl); 2013 Jun; 91(6):749-58. PubMed ID: 23361368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
    Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
    Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
    Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
    J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
    Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
    Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
    Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.
    Lindholm EM; Krohn M; Iadevaia S; Kristian A; Mills GB; Mælandsmo GM; Engebraaten O
    Clin Cancer Res; 2014 Jan; 20(2):404-12. PubMed ID: 24192926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
    Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
    Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.
    Guo XL; Li D; Sun K; Wang J; Liu Y; Song JR; Zhao QD; Zhang SS; Deng WJ; Zhao X; Wu MC; Wei LX
    J Mol Med (Berl); 2013 Apr; 91(4):473-83. PubMed ID: 23052483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
    Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
    Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.
    Hu YL; DeLay M; Jahangiri A; Molinaro AM; Rose SD; Carbonell WS; Aghi MK
    Cancer Res; 2012 Apr; 72(7):1773-83. PubMed ID: 22447568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.